Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Trxade Health Inc (MEDS)

Trxade Health Inc (MEDS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,351
  • Shares Outstanding, K 1,205
  • Annual Sales, $ 11,450 K
  • Annual Income, $ -3,470 K
  • 60-Month Beta 2.01
  • Price/Sales 1.36
  • Price/Cash Flow N/A
  • Price/Book 0.50
Trade MEDS with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.29 +4.07%
on 04/18/24
25.80 -74.63%
on 03/22/24
-14.13 (-68.35%)
since 03/19/24
3-Month
3.69 +77.39%
on 02/08/24
44.56 -85.31%
on 03/11/24
+2.15 (+48.77%)
since 01/19/24
52-Week
3.69 +77.39%
on 02/08/24
44.56 -85.31%
on 03/11/24
+2.05 (+45.46%)
since 04/19/23

Most Recent Stories

More News
EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

/CNW/ - Eat Well Investment Group Inc. (CSE: EWG) (US: EWGFF) (FSE: 6BC0), a leading plant-based food ingredient and CPG company, is pleased to announce it has...

MEDS : 6.50 (-6.20%)
EWG.CN : 0.1700 (unch)
EWGFF : 0.0500 (+150.00%)
Similar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates

Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 2.94% and 39.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

OMIC : 0.4100 (+5.43%)
MEDS : 6.50 (-6.20%)
TRxADE (MEDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

TRxADE (MEDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEDS : 6.50 (-6.20%)
TRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates

TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MEDS : 6.50 (-6.20%)
MEDP : 371.26 (-0.82%)
All You Need to Know About TRxADE (MEDS) Rating Upgrade to Strong Buy

TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

MEDS : 6.50 (-6.20%)
TRxADE (MEDS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

TRxADE (MEDS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend...

MEDS : 6.50 (-6.20%)
All You Need to Know About TRxADE (MEDS) Rating Upgrade to Buy

TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MEDS : 6.50 (-6.20%)
TRxADE (MEDS) Reports Q3 Loss, Lags Revenue Estimates

TRxADE (MEDS) delivered earnings and revenue surprises of 50% and 27.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MEDS : 6.50 (-6.20%)
GDRX : 6.66 (-1.04%)
TRxADE Health (NASDAQ: MEDS) Subsidiary, Bonum Health Enters into Telehealth Services Deal with Wakefern Food Corp.

TRxADE Health, Inc. (NASDAQ: MEDS) is engaged as a health services IT company, which is focused on digitalizing the entire

AAPL : 165.03 (-1.20%)
MEDS : 6.50 (-6.20%)
TRxADE (MEDS) Reports Q2 Loss, Tops Revenue Estimates

TRxADE (MEDS) delivered earnings and revenue surprises of -44.44% and 13.07%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MEDS : 6.50 (-6.20%)
SKIN : 3.34 (-2.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

TRxADE HEALTH INC. is a health services IT company focused on digitalizing the retail pharmacy experience. TRxADE HEALTH INC., formerly known as TRxADE Group Inc., is based in TAMPA, FL.

See More

Key Turning Points

3rd Resistance Point 8.57
2nd Resistance Point 7.98
1st Resistance Point 7.46
Last Price 6.50
1st Support Level 6.35
2nd Support Level 5.76
3rd Support Level 5.24

See More

52-Week High 44.56
Fibonacci 61.8% 28.95
Fibonacci 50% 24.13
Fibonacci 38.2% 19.30
Last Price 6.50
52-Week Low 3.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar